REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets raised its position in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 602.9% during the 3rd quarter, Holdings Channel reports. The firm owned 20,441 shares of the biotechnology company’s stock after buying an additional 17,533 shares during the quarter. BNP Paribas Financial Markets’ holdings in REGENXBIO were worth $214,000 as of its most recent filing with the SEC.

A number of other hedge funds have also modified their holdings of RGNX. FMR LLC increased its holdings in REGENXBIO by 166.8% in the 3rd quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after buying an additional 1,656 shares during the period. nVerses Capital LLC increased its stake in shares of REGENXBIO by 183.3% in the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 2,200 shares during the period. China Universal Asset Management Co. Ltd. raised its holdings in shares of REGENXBIO by 64.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 3,720 shares during the last quarter. Arizona State Retirement System boosted its holdings in REGENXBIO by 20.6% in the second quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock valued at $137,000 after purchasing an additional 1,997 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of REGENXBIO in the 3rd quarter valued at about $146,000. 88.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total transaction of $101,100.00. Following the transaction, the director now directly owns 11,286 shares in the company, valued at $114,101.46. The trade was a 46.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 13.13% of the stock is owned by company insiders.

Analysts Set New Price Targets

RGNX has been the topic of several recent research reports. Chardan Capital restated a “buy” rating and issued a $52.00 price objective on shares of REGENXBIO in a research report on Wednesday, November 20th. Royal Bank of Canada restated an “outperform” rating and set a $35.00 price target on shares of REGENXBIO in a research report on Wednesday, December 11th. StockNews.com upgraded shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Raymond James restated an “outperform” rating and set a $18.00 target price on shares of REGENXBIO in a research report on Thursday, October 10th. Finally, Morgan Stanley restated an “overweight” rating and issued a $22.00 price target on shares of REGENXBIO in a research note on Friday, November 15th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $35.27.

REGENXBIO Price Performance

Shares of REGENXBIO stock opened at $8.54 on Tuesday. The stock has a market capitalization of $423.11 million, a P/E ratio of -1.70 and a beta of 1.24. The business has a 50 day simple moving average of $9.72 and a two-hundred day simple moving average of $11.33. REGENXBIO Inc. has a 12 month low of $8.06 and a 12 month high of $28.80.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.